Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 28, 2015; 21(16): 4911-4918
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4911
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4911
Table 2 Characteristics of chemotherapy
Treatment characteristics | n (%) |
Median duration of first-line therapy (range), d | 105 (6-568) |
First-line therapy | |
Single-agent (Fluoropyrimidine) | 3 (5.5) |
Doublet | 47 (85.5) |
FLO | 38 (69.1) |
FLP | 2 (3.6) |
XP | 2 (3.6) |
FOLFIRI | 2 (3.6) |
Other | 3 (5.5) |
Triplet | 5 (9.1) |
EOX | 2 (3.6) |
FLOT | 2 (3.6) |
TFLP | 1 (1.8) |
Oxaliplatin-based therapy | 42 (76.4) |
Cisplatin-based therapy | 7 (12.7) |
Other therapy | 6 (10.9) |
Trastuzumab containing therapy | 5 (9.1) |
Participation in clinical trial | 3 (5.5) |
Toxicities with dosage reduction | 31 (56.4) |
Polyneuropathy HematotoxicityLeucopeniaThrombopenia | 14 (25.5) 6 (10.9)3 (5.5)3 (5.5) |
Fatigue | 4 (7.3) |
Nausea | 4 (7.3) |
Other | 3 (5.5) |
Toxicities with interruption of treatment | 6 (10.9) |
Polyneuropathy | 2 (3.6) |
Fatigue | 2 (3.6) |
Anaphylaxia | 1 (1.8) |
Infection | 1 (1.8) |
Second-line treatment | 28 (50.9) |
- Citation: Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroenterol 2015; 21(16): 4911-4918
- URL: https://www.wjgnet.com/1007-9327/full/v21/i16/4911.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i16.4911